NICE final guidance recommends Lucentis® as cost-effective treatment for wet AMD, a leading cause of blindness

in
  • Lucentis is only approved therapy to demonstrate improvement in vision and vision-related function in vast majority of wet AMD patients
  • NICE decision secures access to innovative medication for eligible patients with wet AMD in England and Wales